Biocryst Pharmaceuticals (BCRX) Receivables - Other (2011 - 2013)

Biocryst Pharmaceuticals has reported Receivables - Other for 3 years, with the latest figure at $2.4 million in Q3 2013.

• For the quarter ending Q3 2013, Receivables - Other fell 37.13% year-over-year to $2.4 million; the trailing twelve-month figure through Sep 2013 stood at $2.4 million (down 37.13% YoY), and the FY2012 full-year result was $4.6 million, down 21.76% from the prior year.
• Receivables - Other for Q3 2013 stood at $2.4 million, up from $1.0 million in the prior quarter.
• The five-year high for Receivables - Other was $5.8 million in Q4 2011, with the low at $1.0 million in Q2 2013.
• Historically, Receivables - Other has averaged $3.9 million across 3 years, with a median of $4.3 million in 2013.
• Annual changes were most pronounced in 2012 — Receivables - Other fell 21.76% — and 2013, when it tumbled 79.86%.
• Biocryst Pharmaceuticals' Receivables - Other stood at $5.8 million in 2011, then fell by 21.76% to $4.6 million in 2012, then plunged by 48.07% to $2.4 million in 2013.
• The last three Receivables - Other figures came in at $2.4 million (Q3 2013), $1.0 million (Q2 2013), and $4.3 million (Q1 2013), per Business Quant data.